MCID: DRG003
MIFTS: 50

Drug Dependence malady

Categories: Mental diseases

Aliases & Classifications for Drug Dependence

Aliases & Descriptions for Drug Dependence:

Name: Drug Dependence 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9974
ICD9CM 35 304.6 304.60
UMLS 69 C0029792

Summaries for Drug Dependence

Disease Ontology : 12 A substance dependence that involves the continued use of drugs despite problems related to use of the substance.

MalaCards based summary : Drug Dependence is related to hepatitis d and schizophrenia. An important gene associated with Drug Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ethanol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Drug Dependence

Diseases related to Drug Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
id Related Disease Score Top Affiliating Genes
1 hepatitis d 28.9 BDNF CRH DRD2 SLC6A4
2 schizophrenia 28.3 ANKK1 BDNF CNR1 DRD1 DRD2 DRD3
3 personality disorder 28.3 BDNF CNR1 CRH DRD1 DRD2 DRD3
4 drug addiction 11.2
5 substance dependence 11.0
6 cocaine dependence 11.0
7 opiate dependence 10.6
8 barbiturate dependence 10.6
9 malaria 10.6
10 cannabis dependence 10.6
11 hallucinogen dependence 10.6
12 acute contagious conjunctivitis 10.3 DRD2 OPRM1 PDYN
13 peripheral vertigo 10.3 OPRD1 OPRK1 OPRM1
14 apperceptive agnosia 10.2 ANKK1 DRD2 SLC6A4
15 strongyloidiasis 10.2 ANKK1 DRD2 SLC6A4
16 extraosseous chondrosarcoma 10.2 PDYN POMC SLC6A4
17 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.2 CRH DRD2 POMC
18 carotid stenosis 10.2 DRD2 POMC SLC6A4
19 intracranial aneurysm 10.2 ANKK1 DRD2 DRD3
20 conjunctival pigmentation 10.2 CRH SLC6A4
21 basal cell carcinoma 3 10.1 ANKK1 DRD2 OPRM1
22 schizoid personality disorder 10.1 DRD3 SLC6A4
23 adamantinous craniopharyngioma 10.1 CRH DRD2 POMC
24 lichen disease 10.1 CRH POMC SLC6A4
25 fechtner syndrome 10.1 CRH POMC SLC6A4
26 intermittent squint 10.1 CRH POMC
27 18p deletion syndrome 10.1 ANKK1 DRD2 OPRD1 OPRM1 PDYN
28 cecal benign neoplasm 10.1 ANKK1 DRD2 DRD3 SLC6A4
29 alzheimer disease 17 10.1 CRH DRD3 SLC6A4
30 cervicitis 10.0 OPRD1 OPRK1 OPRM1 PENK
31 sphenoorbital meningioma 10.0 DRD2 DRD3
32 c8 deficiency, type ii 10.0 DRD1 DRD2 DRD3 OPRM1
33 pyromania 10.0 DRD1 DRD2 DRD3 SLC6A4
34 postencephalitic parkinson disease 10.0 BDNF DRD2 SLC6A4
35 chronic eosinophilic pneumonia 10.0 BDNF CRH SLC6A4
36 teratoma with malignant transformation 9.9 BDNF DRD2 DRD3
37 autoimmune disease of endocrine system 9.9 CNR1 CRH OPRM1 PDYN POMC
38 triple x syndrome 9.9 CNR1 PENK
39 siberian tick typhus 9.9 BDNF CNR1 PDYN
40 hypoglycemic coma 9.9 BDNF CHRM2 CRH SLC6A4
41 kashin-beck disease 9.9 BDNF CHRM2 CNR1
42 keratosis 9.9 BDNF CRH POMC SLC6A4
43 mucinous adenocarcinoma 9.9 BDNF DRD2 DRD3 SLC6A4
44 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.9 BDNF CRH POMC SLC6A4
45 primary angle-closure glaucoma 9.9 BDNF DRD1 SLC6A4
46 transmitted_by 9.8 DRD2 DRD3 OPRK1 OPRM1 PDYN POMC
47 alcohol dependence 9.8
48 suppurative periapical periodontitis 9.8 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
49 brain glioblastoma multiforme 9.8 BDNF DRD2 DRD3 SLC6A4
50 simultanagnosia 9.8 CNR1 OPRK1 OPRL1 OPRM1 PDYN POMC

Graphical network of the top 20 diseases related to Drug Dependence:



Diseases related to Drug Dependence

Symptoms & Phenotypes for Drug Dependence

MGI Mouse Phenotypes related to Drug Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 OPRL1 OPRM1 PDYN PENK POMC SLC6A4
2 homeostasis/metabolism MP:0005376 10.3 ACKR1 ADH7 BDNF CHRM2 CNR1 CRH
3 growth/size/body region MP:0005378 10.22 DRD2 DRD3 OPRM1 PDYN PENK POMC
4 integument MP:0010771 10.17 BDNF CHRM2 CNR1 CRH DRD1 DRD2
5 nervous system MP:0003631 10.13 DRD2 DRD3 OPRD1 ADH7 BDNF CHRM2
6 adipose tissue MP:0005375 10.08 CNR1 CRH DRD1 DRD2 DRD3 OPRM1
7 digestive/alimentary MP:0005381 10.03 BDNF CNR1 DRD1 DRD2 DRD3 OPRK1
8 no phenotypic analysis MP:0003012 9.81 BDNF CNR1 CRH DRD2 OPRD1 OPRM1
9 normal MP:0002873 9.61 BDNF CNR1 CRH DRD1 DRD2 OPRL1
10 taste/olfaction MP:0005394 8.92 ADH7 BDNF CNR1 DRD2

Drugs & Therapeutics for Drug Dependence

Drugs for Drug Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 802)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
2
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 772 46507594
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
5
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
6
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
7
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
8
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
9
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
10
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
11
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
12
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
13
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
14
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
15
Prazosin Approved Phase 4,Phase 3,Phase 2,Phase 1 19216-56-9 4893
16
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
19
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
20
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 465-65-6 5284596
21
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
22
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
23
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
24
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 113-45-1 4158
25
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 300-62-9 5826 3007
26
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
27
Budesonide Approved Phase 4 51333-22-3 63006 5281004
28
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
29
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
30
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
31
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 537-46-2 10836
32
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
33
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 76-99-3 4095
34
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
35
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
36
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
37
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
38
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 77337-76-9 71158
39
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
40
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
41
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
42
Biperiden Approved Phase 4,Phase 3,Phase 2 514-65-8 2381
43
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
44
Cosyntropin Approved Phase 4 16960-16-0 16129617
45
Guaifenesin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 93-14-1 3516
46
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-41-2 439260
47
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2 69-65-8 453 6251
48
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
49
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 57-83-0 5994
50
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244

Interventional clinical trials:

(show top 50) (show all 2323)
id Name Status NCT ID Phase
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
2 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4
3 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
4 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4
5 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
6 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
8 Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study Unknown status NCT01135602 Phase 4
9 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
10 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
11 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4
12 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
13 Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Unknown status NCT01895894 Phase 4
14 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4
15 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4
16 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
17 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
18 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4
19 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4
20 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4
21 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Unknown status NCT00851942 Phase 4
22 Effect of Daily Nicotine Patch Application on Mechanical Ventilation Weaning in Smoking Patients Unknown status NCT01104896 Phase 4
23 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
24 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
25 Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption Unknown status NCT01494246 Phase 4
26 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
27 Treatment of Hepatitis C in Psychiatric Patients Completed NCT00751426 Phase 4
28 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4
29 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4
30 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4
31 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4
32 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4
33 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4
34 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4
35 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
36 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
37 Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial Completed NCT01760967 Phase 4
38 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4
39 The Whole Day First Grade Program Completed NCT00257088 Phase 4
40 Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic Completed NCT00381043 Phase 4
41 Extended-release Naltrexone for Alcohol Dependence in Primary Care Completed NCT00620750 Phase 4
42 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
43 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4
44 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4
45 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4
46 Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch) Completed NCT00000447 Phase 4
47 Effects of Chantix on Relapse Prevention for Smoking Cessation Completed NCT00948649 Phase 4
48 Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription Completed NCT00244465 Phase 4
49 Varenicline in Drug Treatment Completed NCT01286584 Phase 4
50 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4

Search NIH Clinical Center for Drug Dependence

Genetic Tests for Drug Dependence

Anatomical Context for Drug Dependence

MalaCards organs/tissues related to Drug Dependence:

39
Testes, Brain, Heart, Breast, Cortex, Globus Pallidus, Prefrontal Cortex

Publications for Drug Dependence

Articles related to Drug Dependence:

(show top 50) (show all 573)
id Title Authors Year
1
Estimated probability of becoming a case of drug dependence in relation to duration of drug-taking experience: a functional analysis approach. ( 27356948 )
2016
2
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. ( 27230395 )
2016
3
Evidence for Association Between Low Frequency Variants in CHRNA6/CHRNB3 and Antisocial Drug Dependence. ( 27085880 )
2016
4
Ibogaine for treating drug dependence. What is a safe dose? ( 27426011 )
2016
5
Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial. ( 27428201 )
2016
6
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? ( 27208979 )
2016
7
Evidence of Shared Genome-Wide Additive Genetic Effects on Interpersonal Trauma Exposure and Generalized Vulnerability to Drug Dependence in a Population of Substance Users. ( 27214850 )
2016
8
Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. ( 27046394 )
2016
9
Profile of female patients seeking in-patient treatment for prescription opioid abuse from a tertiary care drug dependence treatment centre from India. ( 26997020 )
2016
10
Barriers in Access to the Treatment for People with Gambling Disorders. Are They Different from Those Experienced by People with Alcohol and/or Drug Dependence? ( 27832520 )
2016
11
A Retrospective Chart Review of Treatment Completers Versus Noncompleters Among In-patients at a Tertiary Care Drug Dependence Treatment Centre in India. ( 27570339 )
2016
12
Drug Dependence Treatment Awareness among Japanese Female Stimulant Drug Offenders. ( 27845738 )
2016
13
Barriers to community-based drug dependence treatment: implications for police roles, collaborations and performance indicators. ( 27435714 )
2016
14
Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. ( 27247820 )
2016
15
Abstinence From Drug Dependence After Bilateral Globus Pallidus Hypoxic-Ischemic Injury. ( 27311800 )
2016
16
Illicit Drug Dependence ( 27227249 )
2016
17
Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. ( 26194548 )
2016
18
Stressful Events and Other Predictors of Remission from Drug Dependence in the United States: Longitudinal Results from a National Survey. ( 27776676 )
2016
19
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence. ( 27424166 )
2016
20
Three Types of Adverse Childhood Experiences, and Alcohol and Drug Dependence Among Adults: An Investigation Using Population-Based Data. ( 27326749 )
2016
21
Mortality and illicit drug dependence among hemodialysis patients in the United States: a retrospective cohort analysis. ( 27278934 )
2016
22
Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and non-Indigenous people who inject drugs. ( 27241554 )
2016
23
WHO Expert Committee on Drug Dependence. Thirty-sixth report. ( 26062388 )
2015
24
Can psychedelic compounds play a part in drug dependence therapy? ( 25561484 )
2015
25
Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. ( 25424661 )
2015
26
Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. ( 26470779 )
2015
27
[Role of intracellular Ca2+ dynamics in the development of drug dependence--Participation of Inositol 1,4,5-trisphosphate receptors]. ( 26255430 )
2015
28
The Two Faces of Social Interaction Reward in Animal Models of Drug Dependence. ( 26088685 )
2015
29
Testing for drugs in exhaled breath collected with ExaBreathAr in a drug dependence population: comparison with data obtained in urine after LC-MS/MS analyses. ( 26222873 )
2015
30
Negative mood reverses devaluation of goal-directed drug-seeking favouring an incentive learning account of drug dependence. ( 26041336 )
2015
31
Association between experience of child abuse and severity of drug addiction measured by the Addiction Severity Index among Japanese drug-dependent patients. ( 25741639 )
2015
32
Stress and Drug Dependence Differentially Modulate Norepinephrine Signaling in Animals with Varied HPA Axis Function. ( 25601230 )
2015
33
Patterns of Methylphenidate Use and Assessment of Its Abuse among the General Population and Individuals with Drug Dependence. ( 26491869 )
2015
34
Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis. ( 25500252 )
2015
35
Salutogenesis: Contextualising place and space in the policies and politics of recovery from drug dependence (UK). ( 26616849 )
2015
36
Treating drug dependence with the aid of ibogaine: A retrospective study. ( 25271214 )
2014
37
Comparison of health care needs of child family members of adults with alcohol or drug dependence versus adults with asthma or diabetes. ( 24799266 )
2014
38
Stigmatization of people with drug dependence in China: A community-based study in Hunan province. ( 24239068 )
2014
39
Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. ( 24685459 )
2014
40
Effects of chronic mild stress on the development of drug dependence in rats. ( 24949570 )
2014
41
Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. ( 25142405 )
2014
42
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. ( 25011627 )
2014
43
Homeless drug users and information technology: a qualitative study with potential implications for recovery from drug dependence. ( 24799073 )
2014
44
Comparison of Health Care Resource use and Costs in Patients with Opioid Prescription Drug Dependence (Opd) Treated with Buprenorphine/Naloxone and Patients without Pharmacological Treatment: Retrospective Analysis of us Public Insurance Claims. ( 27201307 )
2014
45
Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature. ( 23701272 )
2014
46
Self-Efficacy and Social Networks After Treatment for Alcohol or Drug Dependence and Major Depression: Disentangling Person and Time-Level Effects. ( 25347018 )
2014
47
Nicotinic receptor modulation to treat alcohol and drug dependence. ( 25642160 )
2014
48
Translating the semi-structured assessment for drug dependence and alcoholism in the Western Pacific: rationale, study design and reliability of alcohol dependence. ( 24936588 )
2014
49
Neuroimaging in Alcohol and Drug Dependence. ( 24678450 )
2014
50
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. ( 24189487 )
2014

Variations for Drug Dependence

Expression for Drug Dependence

Search GEO for disease gene expression data for Drug Dependence.

Pathways for Drug Dependence

Pathways related to Drug Dependence according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 ACKR1 CHRM2 CNR1 CRH DRD1 DRD2
2
Show member pathways
12.74 ACKR1 CHRM2 CNR1 CRH DRD1 DRD2
3
Show member pathways
12.06 BDNF CHRM2 DRD1 DRD2
4
Show member pathways
11.77 BDNF DRD1 DRD2 PDYN
6
Show member pathways
11.73 CHRM2 DRD1 DRD2 DRD3
7 11.71 OPRD1 OPRM1 POMC
8 11.63 ACKR1 CHRM2 CNR1 DRD3
9 10.83 DRD1 DRD2 DRD3
10 10.28 CRH POMC

GO Terms for Drug Dependence

Cellular components related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.83 CHRM2 CRH OPRK1 PDYN PENK
2 axon GO:0030424 9.78 CNR1 DRD2 OPRM1 PENK
3 neuron projection GO:0043005 9.77 OPRD1 OPRK1 OPRL1 OPRM1 SLC6A4
4 membrane raft GO:0045121 9.76 CNR1 OPRD1 OPRM1 SLC6A4
5 dendrite GO:0030425 9.73 CHRM2 DRD2 OPRK1 OPRM1 PDYN PENK
6 integral component of plasma membrane GO:0005887 9.65 CHRM2 CNR1 DRD1 DRD2 DRD3 OPRD1
7 perikaryon GO:0043204 9.55 CRH DRD2 OPRK1 OPRM1 PENK
8 dendrite membrane GO:0032590 9.49 OPRD1 OPRM1
9 symmetric synapse GO:0032280 9.4 CHRM2 PENK
10 axon terminus GO:0043679 9.1 CHRM2 DRD2 OPRD1 OPRK1 PDYN PENK
11 plasma membrane GO:0005886 10.17 ACKR1 ADH7 CHRM2 CNR1 DRD1 DRD2

Biological processes related to Drug Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.93 DRD1 DRD2 DRD3 OPRK1 OPRM1 PENK
2 response to toxic substance GO:0009636 9.91 DRD2 PENK SLC6A4
3 response to estradiol GO:0032355 9.91 OPRL1 PENK SLC6A4
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.91 CHRM2 CNR1 DRD1 OPRD1 OPRM1
5 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.88 OPRD1 OPRK1 OPRL1 OPRM1
6 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.87 OPRD1 OPRK1 OPRM1
7 memory GO:0007613 9.87 CNR1 DRD1 SLC6A4
8 synapse assembly GO:0007416 9.87 BDNF DRD1 DRD2
9 regulation of sensory perception of pain GO:0051930 9.87 OPRD1 OPRK1 OPRL1 OPRM1
10 neuropeptide signaling pathway GO:0007218 9.87 OPRD1 OPRK1 OPRL1 OPRM1 PDYN PENK
11 learning or memory GO:0007611 9.86 CNR1 CRH DRD3
12 eating behavior GO:0042755 9.86 OPRD1 OPRK1 OPRL1 OPRM1
13 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.85 CHRM2 CNR1 DRD2
14 visual learning GO:0008542 9.85 DRD1 DRD2 DRD3
15 response to nicotine GO:0035094 9.85 CNR1 DRD2 PENK
16 behavioral response to cocaine GO:0048148 9.85 DRD1 DRD2 DRD3 OPRK1
17 sensory perception of pain GO:0019233 9.85 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PENK
18 response to radiation GO:0009314 9.84 OPRK1 OPRM1 PENK
19 synaptic transmission, dopaminergic GO:0001963 9.84 CRH DRD1 DRD2 DRD3
20 associative learning GO:0008306 9.82 CRH DRD1 DRD2
21 negative regulation of adenylate cyclase activity GO:0007194 9.81 DRD2 DRD3 OPRM1
22 response to amphetamine GO:0001975 9.81 DRD1 DRD2 DRD3
23 negative regulation of blood pressure GO:0045776 9.8 CNR1 CRH DRD2 DRD3 OPRL1
24 dopamine receptor signaling pathway GO:0007212 9.79 DRD1 DRD2 DRD3
25 estrous cycle GO:0044849 9.79 OPRK1 OPRL1 OPRM1
26 dopamine metabolic process GO:0042417 9.78 DRD1 DRD2 DRD3
27 prepulse inhibition GO:0060134 9.77 DRD1 DRD2 DRD3
28 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.77 DRD1 DRD3 OPRM1
29 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.75 DRD1 DRD2 DRD3
30 regulation of dopamine secretion GO:0014059 9.74 DRD2 DRD3
31 temperature homeostasis GO:0001659 9.74 DRD1 DRD2
32 negative regulation of cAMP biosynthetic process GO:0030818 9.74 OPRL1 OPRM1
33 startle response GO:0001964 9.74 DRD2 PENK
34 regulation of N-methyl-D-aspartate selective glutamate receptor activity GO:2000310 9.73 CRH OPRM1
35 behavioral response to ethanol GO:0048149 9.73 DRD2 OPRM1
36 maternal behavior GO:0042711 9.73 DRD1 OPRK1
37 grooming behavior GO:0007625 9.73 DRD1 DRD2
38 opioid receptor signaling pathway GO:0038003 9.73 OPRD1 OPRK1 OPRL1 OPRM1
39 positive regulation of urine volume GO:0035810 9.72 DRD2 OPRL1
40 positive regulation of renal sodium excretion GO:0035815 9.72 DRD2 DRD3
41 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3
42 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.72 DRD1 DRD2
43 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 DRD2 OPRL1
44 locomotory exploration behavior GO:0035641 9.71 CRH PENK
45 regulation of synaptic transmission, GABAergic GO:0032228 9.71 CNR1 DRD2
46 G-protein coupled receptor internalization GO:0002031 9.71 DRD2 DRD3
47 striatum development GO:0021756 9.71 DRD1 DRD2
48 behavior GO:0007610 9.71 OPRK1 OPRL1
49 peristalsis GO:0030432 9.7 DRD1 DRD2
50 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD2 DRD3

Molecular functions related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.87 CNR1 DRD1 DRD2 DRD3 OPRD1 OPRL1
2 drug binding GO:0008144 9.71 CHRM2 CNR1 DRD2 DRD3
3 G-protein coupled receptor activity GO:0004930 9.65 ACKR1 CHRM2 CNR1 DRD1 DRD2 DRD3
4 neuropeptide hormone activity GO:0005184 9.61 CRH PDYN PENK
5 dopamine binding GO:0035240 9.54 DRD1 DRD2 DRD3
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.49 DRD2 DRD3
7 opioid receptor binding GO:0031628 9.48 PDYN PENK
8 opioid peptide activity GO:0001515 9.46 PDYN PENK
9 neuropeptide binding GO:0042923 9.46 OPRD1 OPRK1 OPRL1 OPRM1
10 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD1 DRD2 DRD3
11 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Drug Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....